Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 50,241 shares of PLX stock, worth $124,597. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,241
Previous 461,958
89.12%
Holding current value
$124,597
Previous $540,000
90.56%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PLX
# of Institutions
51Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$2.37 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$1.08 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$926,9170.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$826,2640.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$669,6000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $123M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...